Technology | Leads Implantable Devices

Biotronik announced U.S. Food and Drug Administration (FDA) approval and the launch of Sentus ProMRI, the thinnest quadripolar left ventricular lead available in the United States. This introduction completes Biotronik's second-generation ProMRI lead portfolio, which also includes Solia ProMRI and Plexa ProMRI.

Home May 09, 2017
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

May 9, 2017 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific’s Resonate family of implantable ...

Home May 09, 2017
Home
News

May 9, 2017 — The first patient has been enrolled in the U.S. Food and Drug Administration (FDA) approved prospective ...

Home May 09, 2017
Home
News | EP Lab

May 9, 2017 — A manuscript by physicians from Mayo Clinic and Harvard Brigham & Women's Hospital entitled, “Initial ...

Home May 09, 2017
Home
News | Venous Therapies

Medtronic plc recently announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results were presented by Kathleen Gibson, M.D., of Lake Washington Vascular in Bellevue, Wash., at the 2017 Charing Cross Symposium in London. The new data demonstrate the clinical and quality of life benefits of the Medtronic VenaSeal closure system in treating patients with venous reflux disease.

Home May 05, 2017
Home
News | Cardiovascular Business

May 5, 2017 — Northwell Health recently announced that Cindy Grines, M.D., one of the nation’s pre-eminent cardiologists ...

Home May 05, 2017
Home
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)
Feature | Point of Care Testing | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios

Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on ...

Home May 05, 2017
Home
News | Pharmaceuticals

A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found physicians in academic medical centers (AMCs) prescribed fewer of the promoted drugs, and more non-promoted drugs in the same drug classes, following policy changes to restrict marketing activities at those medical centers. The analysis encompassed 16.1 million prescriptions; while the decline observed was modest in terms of percentage, proportionally small changes can represent thousands of prescriptions.

Home May 05, 2017
Home
News | Cardiovascular Information Systems (CVIS)

May 5, 2017 — DASpecialists LLC, a provider of data abstraction and support services for mandated or voluntary ...

Home May 05, 2017
Home
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)

May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist ...

Home May 05, 2017
Home
News | Cardiovascular Surgery

Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that can be caused by open-heart surgery. The findings point to a new potential way to help these hearts recover more completely.

Home May 04, 2017
Home
News | Cardiovascular Business | Jeff Zagoudis

The U.S. House of Representatives on Thursday narrowly approved the American Health Care Act, the legislation designed by House Republican leadership and backed by President Donald Trump to replace the Affordable Care Act (ACA), also known as Obamacare.

Home May 04, 2017
Home
News | Mobile Devices

Spok Inc. recently released the second part of the company's annual mobility in healthcare survey. Spok has been conducting this survey since 2011 to assess mobile workflow enablement trends in hospitals across the country. More than 300 U.S. healthcare professionals responded to this year’s questions about mobile strategy development, bring your own device (BYOD) policies, communications infrastructure and opportunities to improve mobile communications.

Home May 03, 2017
Home
News | Heart Failure

American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3 clinical trial, HEART-FID. This double-blind, multicenter, prospective, randomized, placebo-controlled study will assess the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of patients with heart failure, iron deficiency and a reduced ejection fraction.

Home May 03, 2017
Home
News | Cardio-oncology

Epsilon Imaging Inc. announced a research study using EchoInsight was presented at the American College of Cardiology (ACC) 2017 Annual Scientific Session and Expo conference from a team at Northwestern University.

Home May 03, 2017
Home
Subscribe Now